Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Thursday

Cardiol Therapeutics (NASDAQ:CRDL) is expected to announce its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Cardiol Therapeutics to post earnings of ($0.09) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). On average, analysts expect Cardiol Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Cardiol Therapeutics Stock Up 2.0%

Shares of Cardiol Therapeutics stock opened at $1.50 on Wednesday. The company has a market cap of $173.84 million, a P/E ratio of -5.36 and a beta of 0.72. The firm’s 50 day moving average price is $1.14 and its 200-day moving average price is $1.17. Cardiol Therapeutics has a 52-week low of $0.88 and a 52-week high of $1.71.

Institutional Trading of Cardiol Therapeutics

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE increased its stake in Cardiol Therapeutics by 136.2% during the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after purchasing an additional 15,255 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Cardiol Therapeutics during the third quarter valued at $249,000. Virtu Financial LLC purchased a new stake in shares of Cardiol Therapeutics during the third quarter valued at $154,000. Citadel Advisors LLC increased its position in shares of Cardiol Therapeutics by 1,132.6% in the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after acquiring an additional 425,862 shares during the period. Finally, Susquehanna International Group LLP increased its position in shares of Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock valued at $100,000 after acquiring an additional 73,375 shares during the period. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CRDL. HC Wainwright restated a “buy” rating on shares of Cardiol Therapeutics in a research note on Tuesday, July 14th. Wall Street Zen downgraded Cardiol Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Cardiol Therapeutics has a consensus rating of “Hold” and an average price target of $8.50.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.